America's Health Secretary Injects Unproven Peptides (But Wants More Vaccine Research)

Vaccines have decades of clinical trial data behind them. Peptides like BPC-157 have about 192 PubMed papers accumulated over 30-plus years of study, and the vast majority are preclinical, meaning they were tested on cells or animals, not people. No conclusive human proof of efficacy exists.

Yet Kennedy treats vaccines as suspect and peptides as promising. He's pushed to amend guidelines for the Advisory Committee on Immunization Practices (ACIP) to highlight potential vaccine harms. He's promoted vitamin A as a treatment that "dramatically reduces deaths" from measles. He's restricted FDA support for mRNA research.

Meanwhile, his evidence for peptides? Largely anecdotes. Gym bros reporting that their shoulder feels better. Health influencers like Andrew Huberman singing the praises of BPC-157 on podcasts and social media.

The agency is supposed to be a consistent referee, not one that calls fouls selectively based on vibes.

Medical Libertarianism, Applied Unevenly

Kennedy's defenders frame his stance as philosophically consistent. Lewis Grossman, a health law professor at American University, describes it as "medical libertarianism": people should have the right to choose their own treatments, whether that means declining a vaccine or injecting a peptide.

It echoes the deregulation battles of the 1970s, when vitamin manufacturers fought (and won) the right to block the FDA from imposing new potency limits and from reclassifying high-potency supplements as drugs. The logic is simple: my body, my choice.

But here's where it falls apart. Kennedy isn't just declining treatments for himself; he's reshaping federal policy. He's making it harder for Americans to access vaccines while making it easier to access peptides that haven't passed the same safety bar. That's not libertarianism. That's picking winners and losers based on personal preference.

The inconsistency runs deeper than one person, too. Red states that resisted COVID vaccine mandates have simultaneously passed laws restricting other medical decisions. The pattern suggests that "medical freedom" gets invoked when it's convenient, not when it's principled.

Why Biotech Should Care

This isn't just a culture-war skirmish. It has real implications for drug development and market access.

If the FDA reclassifies 14 peptides to Category 1, compounding pharmacies can start selling them with a prescription. That creates a strange incentive problem: why would any company spend hundreds of millions on clinical trials for a peptide that's already available through a compounder? The entire drug approval pipeline depends on the idea that you prove your product works before you sell it. Kennedy's approach inverts that logic.

For biotech companies working on regenerative therapies, peptide-based drugs, or adjacent spaces, the regulatory landscape just got murkier. The rules might change based on who's in charge and what they personally inject, not based on data.

And for public health more broadly, the erosion of trust cuts both ways. If the government's top health official promotes treatments without clinical evidence, it undermines the case for evidence-based medicine everywhere. The same skepticism Kennedy directs at vaccines could just as easily be turned on the peptides he loves; after all, where are the Phase 3 trials?

The Bigger Picture

The FDA exists because people used to sell radium water as a health tonic. The entire modern regulatory framework is built on a simple principle: prove it works, prove it's safe, then sell it. That principle doesn't have a carve-out for things that feel natural, or things your favorite podcaster recommends.

Kennedy's position puts the nation's top health agency in an impossible spot. You can't demand more evidence for vaccines while waving through peptides on vibes and anecdotes. Well, you can. But you shouldn't expect anyone to take your commitment to science seriously afterward.

The STAT analysis didn't mince words, and neither should we. Consistency isn't optional when you're setting health policy for 330 million people. Right now, the person holding that responsibility is applying a different standard depending on whether he likes the treatment. And that should worry everyone in biotech, regardless of how they feel about peptides or vaccines.

The CAR-T Startup Betting $110M It Can Crack Liver Cancer

A Shanghai biotech just raised $110 million to chase what nobody has achieved: a CAR-T therapy that actually works against solid tumors. Oricell Therapeutics is betting it can crack liver cancer and IPO on the other side.